{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:37:59Z","timestamp":1790656679082,"version":"4.1.0"},"reference-count":91,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,8,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The introduction of imatinib in the treatment of chronic myeloid leukemia (CML) represents the most successful example of targeted therapy in human cancer. However, leukemic stem cells are insensitive to tyrosine kinase inhibitors (TKIs) and contribute to the persistence of disease by representing a reservoir of selfrenewing cells that replenish the disease after drug discontinuation. This finding has refocused the interest of scientists toward drug combinations, ie, treating with TKIs and simultaneously targeting alternative survival mechanisms. One candidate target mechanism is autophagy, a cellular recycling process that acts as a cytoprotective shield in CML cells in response to TKI-induced stress and in other cancer cells surviving in an inhospitable microenvironment. On that basis, inhibition of autophagy has now become an exciting option for combination treatment in cancer, and clinical trials have been initiated in solid and hemopoietic tumors such as CML, chronic lymphocytic leukemia, and multiple myeloma. This review describes the biology of CML and elucidates how the molecular driver BCR-ABL led to the development of TKIs. We then discuss the molecular regulation of autophagy and the potential for autophagy inhibition as the next step in our attempt to tackle the problem of CML persistence to offer a curative option.<\/jats:p>","DOI":"10.1182\/blood-2011-01-330621","type":"journal-article","created":{"date-parts":[[2011,6,22]],"date-time":"2011-06-22T05:04:03Z","timestamp":1308719043000},"page":"2035-2043","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":100,"title":["Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML"],"prefix":"10.1182","volume":"118","author":[{"given":"G. Vignir","family":"Helgason","sequence":"first","affiliation":[{"name":"Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Karvela","sequence":"additional","affiliation":[{"name":"Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa L.","family":"Holyoake","sequence":"additional","affiliation":[{"name":"Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111807563351100_B1","first-page":"85","article-title":"Chromosome studies on normal and leukemic human leukocytes.","volume":"25","author":"Nowell","year":"1960","journal-title":"J Natl Cancer Inst"},{"issue":"5405","key":"2019111807563351100_B2","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"issue":"1","key":"2019111807563351100_B3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0092-8674(84)90077-1","article-title":"Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22.","volume":"36","author":"Groffen","year":"1984","journal-title":"Cell"},{"issue":"3","key":"2019111807563351100_B4","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/0092-8674(84)90438-0","article-title":"An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity.","volume":"37","author":"Konopka","year":"1984","journal-title":"Cell"},{"issue":"4944","key":"2019111807563351100_B5","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome.","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"issue":"23","key":"2019111807563351100_B6","doi-asserted-by":"crossref","first-page":"9312","DOI":"10.1073\/pnas.85.23.9312","article-title":"Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr\/abl protein.","volume":"85","author":"Daley","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"2019111807563351100_B7","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia.","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"issue":"7","key":"2019111807563351100_B8","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1182\/blood.V88.7.2410.bloodjournal8872410","article-title":"Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR\/ABL with C3\/A2 junction).","volume":"88","author":"Pane","year":"1996","journal-title":"Blood"},{"issue":"9","key":"2019111807563351100_B9","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1084\/jem.189.9.1399","article-title":"The P190, P210, and P230 forms of the BCR\/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.","volume":"189","author":"Li","year":"1999","journal-title":"J Exp Med"},{"issue":"1","key":"2019111807563351100_B10","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0092-8674(05)80094-7","article-title":"BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein.","volume":"75","author":"Pendergast","year":"1993","journal-title":"Cell"},{"issue":"4","key":"2019111807563351100_B11","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/j.1460-2075.1994.tb06319.x","article-title":"Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway.","volume":"13","author":"Puil","year":"1994","journal-title":"EMBO J"},{"issue":"7","key":"2019111807563351100_B12","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc839","article-title":"The phosphatidylinositol 3-Kinase AKT pathway in human cancer.","volume":"2","author":"Vivanco","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"2019111807563351100_B13","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1182\/blood.V86.2.726.bloodjournal862726","article-title":"Phosphatidylinositol-3 kinase activity is regulated by BCR\/ABL and is required for the growth of Philadelphia chromosome-positive cells.","volume":"86","author":"Skorski","year":"1995","journal-title":"Blood"},{"issue":"2","key":"2019111807563351100_B14","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/blood.V96.2.676","article-title":"Versatility of BCR\/ABL-expressing leukemic cells in circumventing proapoptotic BAD effects.","volume":"96","author":"Salomoni","year":"2000","journal-title":"Blood"},{"issue":"2","key":"2019111807563351100_B15","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1535-6108(03)00020-5","article-title":"BCR\/ABL activates mdm2 mRNA translation via the La antigen.","volume":"3","author":"Trotta","year":"2003","journal-title":"Cancer Cell"},{"issue":"Pt 2","key":"2019111807563351100_B16","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1042\/bj3440427","article-title":"Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation.","volume":"344","author":"Nave","year":"1999","journal-title":"Biochem J"},{"issue":"9","key":"2019111807563351100_B17","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1073\/pnas.0400063101","article-title":"Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs.","volume":"101","author":"Mohi","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2019111807563351100_B18","first-page":"63","article-title":"FoxO tumor suppressors and BCR-ABL\u2013induced leukemia: a matter of evasion of apoptosis.","volume":"1785","author":"Jagani","year":"2008","journal-title":"Biochim Biophys Acta"},{"issue":"11","key":"2019111807563351100_B19","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1073\/pnas.0731871100","article-title":"Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOXO3a transcription factor.","volume":"100","author":"Ghaffari","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"2019111807563351100_B20","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1182\/blood-2005-10-4110","article-title":"STAT5 signaling is required for the efficient induction and maintenance of CML in mice.","volume":"107","author":"Ye","year":"2006","journal-title":"Blood"},{"issue":"3","key":"2019111807563351100_B21","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/emmm.201000062","article-title":"Stat5 is indispensable for the maintenance of bcr\/abl-positive leukaemia.","volume":"2","author":"Hoelbl","year":"2010","journal-title":"EMBO Mol Med"},{"issue":"12","key":"2019111807563351100_B22","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1182\/blood-2009-10-248211","article-title":"High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia.","volume":"117","author":"Warsch","year":"2011","journal-title":"Blood"},{"issue":"22","key":"2019111807563351100_B23","doi-asserted-by":"crossref","first-page":"12804","DOI":"10.1073\/pnas.96.22.12804","article-title":"Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia.","volume":"96","author":"Jiang","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2019111807563351100_B24","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/sj.leu.2402444","article-title":"Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia.","volume":"16","author":"Holyoake","year":"2002","journal-title":"Leukemia"},{"issue":"7","key":"2019111807563351100_B25","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1172\/JCI41246","article-title":"Chronic myeloid leukemia: mechanisms of blastic transformation.","volume":"120","author":"Perrotti","year":"2010","journal-title":"J Clin Invest"},{"issue":"7","key":"2019111807563351100_B26","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia.","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"issue":"7","key":"2019111807563351100_B27","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia.","volume":"110","author":"O'Hare","year":"2007","journal-title":"Blood"},{"issue":"35","key":"2019111807563351100_B28","doi-asserted-by":"crossref","first-page":"32214","DOI":"10.1074\/jbc.M111525200","article-title":"Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571.","volume":"277","author":"Corbin","year":"2002","journal-title":"J Biol Chem"},{"issue":"27","key":"2019111807563351100_B29","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-iperazin\u2013yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays.","volume":"47","author":"Lombardo","year":"2004","journal-title":"J Med Chem"},{"issue":"24","key":"2019111807563351100_B30","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"issue":"24","key":"2019111807563351100_B31","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"issue":"24","key":"2019111807563351100_B32","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"issue":"24","key":"2019111807563351100_B33","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111807563351100_B34","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell"},{"issue":"2","key":"2019111807563351100_B35","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1158\/1078-0432.CCR-09-3314","article-title":"Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia.","volume":"17","author":"O'Hare","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2019111807563351100_B36","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.ccr.2011.03.003","article-title":"Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036.","volume":"19","author":"Chan","year":"2011","journal-title":"Cancer Cell"},{"key":"2019111807563351100_B37","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-10-3224","article-title":"The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile.","author":"Eide","year":"2011","journal-title":"Cancer Res"},{"issue":"26","key":"2019111807563351100_B38","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N Engl J Med"},{"key":"2019111807563351100_B39","unstructured":"ClinicalTrials.gov\n          Accessed April 14, 2011\n          \n            http:\/\/www.clinicaltrials.gov\/ct2\/home"},{"issue":"10","key":"2019111807563351100_B40","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/leu.2010.185","article-title":"Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.","volume":"24","author":"Ross","year":"2010","journal-title":"Leukemia"},{"issue":"8","key":"2019111807563351100_B41","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2009-11-255109","article-title":"In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib.","volume":"116","author":"Sobrinho-Simoes","year":"2010","journal-title":"Blood"},{"issue":"12","key":"2019111807563351100_B42","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2002-09-2780","article-title":"Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.","volume":"101","author":"Bhatia","year":"2003","journal-title":"Blood"},{"issue":"1","key":"2019111807563351100_B43","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"issue":"9","key":"2019111807563351100_B44","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1182\/blood-2006-11-057521","article-title":"Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells.","volume":"109","author":"Jorgensen","year":"2007","journal-title":"Blood"},{"issue":"4","key":"2019111807563351100_B45","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood-2007-05-092056","article-title":"Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src\/Abl kinase inhibitor SKI-606.","volume":"111","author":"Konig","year":"2008","journal-title":"Blood"},{"issue":"11","key":"2019111807563351100_B46","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"issue":"11","key":"2019111807563351100_B47","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"2019111807563351100_B48","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.","volume":"121","author":"Corbin","year":"2011","journal-title":"J Clin Invest"},{"issue":"5","key":"2019111807563351100_B49","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1172\/JCI35660","article-title":"Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.","volume":"119","author":"Bellodi","year":"2009","journal-title":"J Clin Invest"},{"issue":"7","key":"2019111807563351100_B50","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.4161\/auto.5.7.9509","article-title":"Targeted therapies and autophagy: new insights from chronic myeloid leukemia.","volume":"5","author":"Salomoni","year":"2009","journal-title":"Autophagy"},{"issue":"22","key":"2019111807563351100_B51","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1101\/gad.1599207","article-title":"Autophagy: process and function.","volume":"21","author":"Mizushima","year":"2007","journal-title":"Genes Dev"},{"issue":"4","key":"2019111807563351100_B52","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S1534-5807(04)00099-1","article-title":"Development by self-digestion: molecular mechanisms and biological functions of autophagy.","volume":"6","author":"Levine","year":"2004","journal-title":"Dev Cell"},{"issue":"7","key":"2019111807563351100_B53","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1091\/mbc.e08-12-1249","article-title":"ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery.","volume":"20","author":"Jung","year":"2009","journal-title":"Mol Biol Cell"},{"issue":"6016","key":"2019111807563351100_B54","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1126\/science.1196371","article-title":"Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy.","volume":"331","author":"Egan","year":"2011","journal-title":"Science"},{"issue":"2","key":"2019111807563351100_B55","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/ncb2152","article-title":"AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1.","volume":"13","author":"Kim","year":"2011","journal-title":"Nat Cell Biol"},{"issue":"7","key":"2019111807563351100_B56","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1091\/mbc.e08-12-1248","article-title":"Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy.","volume":"20","author":"Hosokawa","year":"2009","journal-title":"Mol Biol Cell"},{"issue":"7","key":"2019111807563351100_B57","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/ncb1740","article-title":"Beclin1-binding UVRAG targets the class C Vps complex to coordinate autophagosome maturation and endocytic trafficking.","volume":"10","author":"Liang","year":"2008","journal-title":"Nat Cell Biol"},{"issue":"10","key":"2019111807563351100_B58","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1038\/sj.emboj.7601689","article-title":"Functional and physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1.","volume":"26","author":"Maiuri","year":"2007","journal-title":"EMBO J"},{"issue":"6","key":"2019111807563351100_B59","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.cell.2005.07.002","article-title":"Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy.","volume":"122","author":"Pattingre","year":"2005","journal-title":"Cell"},{"issue":"2","key":"2019111807563351100_B60","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.molcel.2006.12.009","article-title":"Control of macroautophagy by calcium, calmodulin-dependent kinase kinase-beta, and Bcl-2.","volume":"25","author":"Hoyer-Hansen","year":"2007","journal-title":"Mol Cell"},{"issue":"7","key":"2019111807563351100_B61","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/ncb1426","article-title":"Autophagic and tumour suppressor activity of a novel Beclin1-binding protein UVRAG.","volume":"8","author":"Liang","year":"2006","journal-title":"Nat Cell Biol"},{"issue":"3","key":"2019111807563351100_B62","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/35056522","article-title":"Molecular dissection of autophagy: two ubiquitin-like systems.","volume":"2","author":"Ohsumi","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"9","key":"2019111807563351100_B63","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/embor.2008.163","article-title":"The Atg8 and Atg12 ubiquitin-like conjugation systems in macroautophagy. \u2018Protein modifications: beyond the usual suspects\u2019 review series.","volume":"9","author":"Geng","year":"2008","journal-title":"EMBO Rep"},{"issue":"7","key":"2019111807563351100_B64","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/nrm2708","article-title":"Dynamics and diversity in autophagy mechanisms: lessons from yeast.","volume":"10","author":"Nakatogawa","year":"2009","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"21","key":"2019111807563351100_B65","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1093\/emboj\/19.21.5720","article-title":"LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing.","volume":"19","author":"Kabeya","year":"2000","journal-title":"EMBO J"},{"issue":"2","key":"2019111807563351100_B66","doi-asserted-by":"crossref","first-page":"151","DOI":"10.4161\/auto.5338","article-title":"Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes.","volume":"4","author":"Klionsky","year":"2008","journal-title":"Autophagy"},{"issue":"1","key":"2019111807563351100_B67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4161\/auto.1.1.1270","article-title":"Maturation of autophagic vacuoles in Mammalian cells.","volume":"1","author":"Eskelinen","year":"2005","journal-title":"Autophagy"},{"issue":"10","key":"2019111807563351100_B68","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/ncb1007-1102","article-title":"Autophagosome formation: core machinery and adaptations.","volume":"9","author":"Xie","year":"2007","journal-title":"Nat Cell Biol"},{"issue":"7","key":"2019111807563351100_B69","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1093\/carcin\/bgr031","article-title":"The multiple roles of autophagy in cancer.","volume":"32","author":"Rosenfeldt","year":"2011","journal-title":"Carcinogenesis"},{"issue":"4","key":"2019111807563351100_B70","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/nrd2272","article-title":"Potential therapeutic applications of autophagy.","volume":"6","author":"Rubinsztein","year":"2007","journal-title":"Nat Rev Drug Discov"},{"issue":"6762","key":"2019111807563351100_B71","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/45257","article-title":"Induction of autophagy and inhibition of tumorigenesis by beclin 1.","volume":"402","author":"Liang","year":"1999","journal-title":"Nature"},{"issue":"25","key":"2019111807563351100_B72","doi-asserted-by":"crossref","first-page":"15077","DOI":"10.1073\/pnas.2436255100","article-title":"Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor.","volume":"100","author":"Yue","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2019111807563351100_B73","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ccr.2006.06.001","article-title":"Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis.","volume":"10","author":"Degenhardt","year":"2006","journal-title":"Cancer Cell"},{"issue":"1","key":"2019111807563351100_B74","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1247\/csf.23.33","article-title":"Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells.","volume":"23","author":"Yamamoto","year":"1998","journal-title":"Cell Struct Funct"},{"issue":"16","key":"2019111807563351100_B75","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1038\/onc.2010.561","article-title":"Autophagy is essential to suppress cell stress and to allow BCR-Abl\u2013mediated leukemogenesis.","volume":"30","author":"Altman","year":"2011","journal-title":"Oncogene"},{"issue":"2","key":"2019111807563351100_B76","doi-asserted-by":"crossref","first-page":"229","DOI":"10.4161\/auto.7.2.14125","article-title":"FIP200, an essential component of mammalian autophagy is indispensible for fetal hematopoiesis.","volume":"7","author":"Liu","year":"2011","journal-title":"Autophagy"},{"issue":"3","key":"2019111807563351100_B77","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1084\/jem.20101145","article-title":"The autophagy protein Atg7 is essential for hematopoietic stem cell maintenance.","volume":"208","author":"Mortensen","year":"2011","journal-title":"J Exp Med"},{"key":"2019111807563351100_B78","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3109\/10428194.2010.546913","article-title":"Inhibition of autophagy: a new strategy to enhance sensitivity of chronic myeloid leukemia stem cells to tyrosine kinase inhibitors.","volume":"52","author":"Calabretta","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2019111807563351100_B79","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1172\/JCI28833","article-title":"Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma.","volume":"117","author":"Amaravadi","year":"2007","journal-title":"J Clin Invest"},{"issue":"5","key":"2019111807563351100_B80","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.toxicon.2006.01.010","article-title":"Contributions of autophagic and apoptotic mechanisms to CrTX-induced death of K562 cells.","volume":"47","author":"Yan","year":"2006","journal-title":"Toxicon"},{"issue":"1","key":"2019111807563351100_B81","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1182\/blood-2006-10-050260","article-title":"Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl\u2013mediated drug resistance.","volume":"110","author":"Carew","year":"2007","journal-title":"Blood"},{"issue":"2","key":"2019111807563351100_B82","first-page":"201","article-title":"Targeting autophagy: a novel anticancer strategy with therapeutic implications for imatinib resistance.","volume":"2","author":"Carew","year":"2008","journal-title":"Biologics"},{"issue":"11","key":"2019111807563351100_B83","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1038\/cdd.2008.107","article-title":"The Bcr-Abl kinase inhibitor INNO-406 induces autophagy and different modes of cell death execution in Bcr-Abl\u2013positive leukemias.","volume":"15","author":"Kamitsuji","year":"2008","journal-title":"Cell Death Differ"},{"issue":"11","key":"2019111807563351100_B84","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1111\/j.1349-7006.2008.00932.x","article-title":"Autophagy and autophagic cell death are next targets for elimination of the resistance to tyrosine kinase inhibitors.","volume":"99","author":"Mishima","year":"2008","journal-title":"Cancer Sci"},{"issue":"1","key":"2019111807563351100_B85","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/ajh.21914","article-title":"Autophagy induction by Bcr-Abl\u2013expressing cells facilitates their recovery from a targeted or nontargeted treatment.","volume":"86","author":"Crowley","year":"2011","journal-title":"Am J Hematol"},{"issue":"28","key":"2019111807563351100_B86","doi-asserted-by":"crossref","first-page":"12469","DOI":"10.1073\/pnas.1005114107","article-title":"Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL\u2013expressing leukemic cells.","volume":"107","author":"Carayol","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2019111807563351100_B87","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1158\/0008-5472.CAN-09-3537","article-title":"Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62\/SQSTM1 expression and AMPK activation.","volume":"70","author":"Puissant","year":"2010","journal-title":"Cancer Res"},{"issue":"51","key":"2019111807563351100_B88","doi-asserted-by":"crossref","first-page":"35941","DOI":"10.1074\/jbc.M804543200","article-title":"Abl kinases regulate autophagy by promoting the trafficking and function of lysosomal components.","volume":"283","author":"Yogalingam","year":"2008","journal-title":"J Biol Chem"},{"key":"2019111807563351100_B89","article-title":"Autophagy is essential to suppress cell stress and to allow BCR-Abl\u2013mediated leukemogenesis.","author":"Altman","year":"2010","journal-title":"Oncogene"},{"issue":"17","key":"2019111807563351100_B90","doi-asserted-by":"crossref","first-page":"5308","DOI":"10.1158\/1078-0432.CCR-07-5023","article-title":"The double-edged sword of autophagy modulation in cancer.","volume":"15","author":"White","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2019111807563351100_B91","first-page":"220","article-title":"Autophagy is a therapeutic target in anticancer drug resistance.","volume":"1806","author":"Chen","year":"2010","journal-title":"Biochim Biophys Acta"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/8\/2035\/1347802\/zh803411002035.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/8\/2035\/1347802\/zh803411002035.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T13:11:17Z","timestamp":1574082677000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/8\/2035\/29428\/Kill-one-bird-with-two-stones-potential-efficacy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,25]]},"references-count":91,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,8,25]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-01-330621","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,25]]}}}